| Fellow Investor, The global wound care market is booming! It's projected to grow from $20.8 billion in 2022 to $27.2 billion by 2027… And the U.S. advanced wound care market alone is poised to reach 17.7 billion in 2027, up from 11.2 billion in 2022. One little-known MedTech company stands out for its astronomical growth potential. Offering cost savings, enhanced patient comfort, fewer applications, and improved compliance with treatment protocols… Their revolutionary products have a huge competitive advantage for post-surgical and diabetic wound care – both multi-billion-dollar markets. They've already seen massive growth from the nationwide rollout of their proprietary products for tissue wounds. In their most recent quarter, the company reported year over year revenue growth of over 2,250%… And increased net income by almost 500% from the year ago quarter! A leading small-cap research firm recently raised its price target on the company's stock to $34.25 from its current share price of under $15.00. A no-fluff report reveals all the details on this emerging gem in the MedTech space… Including the company name and ticker – free of charge, no strings attached. Best of luck in all your investments! ETF Dynamics does not advise its clients or any other person whether or not to buy or sell or take positions in securities. We are not registered as a broker, broker-dealer, investment adviser, agent or representative of the U.S. Securities and Exchange Commission, or any similar authority. We do not teach or recommend to any client their financial suitability to trade equities. All trading involves high risk and you can lose a substantial amount of money. The content provided in this email is a source of information only. The report has been prepared by a third party and ETF Dynamics, LLC is in no way responsible for its content. ETF Dynamics, LLC is receiving compensation for sending this email. This information is not a recommendation to buy, sell or hold any securities or other investments. All statements and expressions are the opinion of the author only and should not be construed as investment advice. This information has been prepared without taking into account your investment objectives or financial situation and is presented for illustrative and educational purposes only.  |
|
Post a Comment
Post a Comment